New Career Opportunities at IVI
IVI has announced two new job opportunities at IVI: Research Manager Operations Manager Please visit our Careers page for job details and application instructions. If you have any questions, please feel free to contact us [...]
PRESS RELEASE: IVI Convenes First-of-its-Kind Multi-Stakeholder Summit to Accelerate Aligning Value Assessment Methods with Real-World Decision Needs
Participants Define Consensus Expectations and Prioritize Research Agenda to Improve Value Assessment Methods Alexandria, VA – March 17, 2020 – The Innovation and Value Initiative (IVI), a research-based non-profit improving the science and practice of [...]
The Ascendency of Value Assessment
Value assessment is a hot topic in healthcare. But how can it be improved so it's more relevant to answering the most important questions to patients, payers and providers? In this commentary, Jennifer Bright explains [...]
PRESS RELEASE: Dr. Patricia Deverka Appointed as IVI’s First Chief Science Officer
IVI is thrilled to announce Pat Deverka, MD has joined our organization as our first Chief Science Officer. Dr. Deverka. Dr. Deverka brings to IVI more than three decades of experience in health economic [...]
PRESS RELEASE: IVI Announces Six New Members to Board of Directors
IVI is pleased to announce the latest additions to our diverse and growing Board of Directors. Read the full press release here to learn who is helping us drive value assessment to the next level [...]
What’s in Store for 2020?
Jennifer Bright discusses the following three trends that began in 2019 and will pick up steam this year: Increased demand for value information for drugs; Increased number of voices asking whether value assessment is done [...]
IVI Unveils Updates to Rheumatoid Arthritis Model
The Center for Biosimilars writes about IVI's recent updates to their IVI-RA value model to include biosimilars, triple therapy, Janus kinase (JAK) inhibitors, sarilumab, as well as updated treatment effect estimates based on additional randomized [...]
PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates
IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment [...]
Expanding Value Assessment Beyond Drugs
Jennifer Bright writes in Morning Consult that while we've made progress assessing the value of biopharmaceuticals, more focus is needed to develop bout transparent, patient-centered value assessment methods in healthcare technologies beyond drugs. Read the [...]
PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors
As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions [...]
IVI Showcases OSVP at HealthEconomics.com’s “Big Ideas Accelerating Change” Challenge
As one of the nine finalists in HealthEconomics.com's inaugural challenge competition to accelerate change in health economics and outcomes research, IVI's Mark Linthicum offered a compelling case for how IVI's Open-Source Value Platform (OSVP) is [...]
IVI Submits Comments on ICER Draft Evidence Report on JAK Inhibitors for RA
IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling [...]